MARAVAI LIFESCIENCES HOLDINGS, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Maravai reported Q3 2026 revenue of $45.9M (+10.1% YoY), with TriLink mRNA products up 28% and Cygnus up 7.5%. The company raised full-year 2026 revenue guidance to $212–216M (from $205–215M) and Adjusted EBITDA guidance to $40–42M (from $33–35M). Nine-month revenue grew 20.1% to $163.1M; net loss improved to $(52.0)M vs. $(167.7)M prior year, partly due to absence of $42.9M goodwill impairment.
Why this rating
Guidance raise (~3–5% revenue midpoint, +27% EBITDA midpoint) is material for $300M market-cap firm. mRNA momentum promising; but company still deeply unprofitable GAAP, carrying debt, and vulnerable to customer concentration risk.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.